Free Trial

TriSalus Life Sciences (NASDAQ:TLSI) Posts Earnings Results, Meets Estimates

TriSalus Life Sciences logo with Medical background
Remove Ads

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) released its earnings results on Thursday. The company reported ($0.35) EPS for the quarter, hitting analysts' consensus estimates of ($0.35), Zacks reports. The business had revenue of $8.26 million for the quarter, compared to the consensus estimate of $8.12 million. TriSalus Life Sciences updated its FY 2025 guidance to EPS.

TriSalus Life Sciences Price Performance

Shares of TLSI traded down $0.07 during midday trading on Monday, hitting $5.55. 24,879 shares of the company traded hands, compared to its average volume of 42,895. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.42. The firm has a market cap of $169.24 million, a P/E ratio of -2.23 and a beta of 0.48. The stock has a 50-day moving average of $5.40 and a 200-day moving average of $4.73.

Insider Activity

In other news, CFO James Emmett Young purchased 6,000 shares of the firm's stock in a transaction dated Wednesday, February 5th. The shares were purchased at an average price of $5.65 per share, with a total value of $33,900.00. Following the completion of the acquisition, the chief financial officer now owns 30,000 shares in the company, valued at $169,500. This trade represents a 25.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Sean Murphy acquired 15,000 shares of the company's stock in a transaction that occurred on Monday, January 27th. The shares were acquired at an average cost of $5.31 per share, with a total value of $79,650.00. Following the purchase, the insider now directly owns 182,732 shares of the company's stock, valued at $970,306.92. This trade represents a 8.94 % increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 54,856 shares of company stock worth $294,608. 32.80% of the stock is owned by company insiders.

Remove Ads

Analyst Ratings Changes

Several research firms recently commented on TLSI. Roth Mkm reiterated a "buy" rating and issued a $11.00 price objective on shares of TriSalus Life Sciences in a research note on Friday, January 24th. Canaccord Genuity Group restated a "buy" rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a research note on Friday. Lake Street Capital initiated coverage on TriSalus Life Sciences in a research note on Thursday, February 13th. They set a "buy" rating and a $10.00 price target for the company. Finally, Cantor Fitzgerald started coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an "overweight" rating and a $10.00 price objective for the company. Eight research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $11.56.

Get Our Latest Stock Analysis on TriSalus Life Sciences

TriSalus Life Sciences Company Profile

(Get Free Report)

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

See Also

Earnings History for TriSalus Life Sciences (NASDAQ:TLSI)

Should You Invest $1,000 in TriSalus Life Sciences Right Now?

Before you consider TriSalus Life Sciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.

While TriSalus Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Best ETFs for Spring 2025: Strong and Steady Investing

Best ETFs for Spring 2025: Strong and Steady Investing

Whether you're after broad market exposure, dividend income, bonds, or even gold, we've got picks that can help you navigate the current investing landscape.

Related Videos

Massive Buybacks: 3 Stocks Insiders Are Buying Up
Volatility-Proof Your Portfolio with These 7 ETFs

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads